A putative class action filed in federal court in Newark claims Sanofi US is engaged in unlawful sales practices designed to encourage doctors to prescribe its drugs.
The suit claims Sanofi continues to engage in practices similar to ones that were banned in agreements it signed with federal officials in 2007, 2009 and 2012, when the company was accused of misrepresenting to Medicare and Medicaid the average prices of its drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
